---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-015818"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2025-12-05T23:59:59+00:00"
generated_at: "2026-05-16T14:17:35.023934+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics reports 89.8% ORR and 77.6% CR in LOTIS-7 trial of ZYNLONTA + glofitamab in r/r DLBCL

## Summary
- Best ORR 89.8% (44/49); CR rate 77.6% (38/49) across dose levels.
- At 150 µg/kg dose, ORR 85.7% and CR 75.0%.
- In primary refractory patients (n=25): ORR 80%, CR 64%.
- Of 8 prior CAR-T patients, 6 achieved CR.
- Grade 3+ neutropenia (32.7%); manageable safety profile overall.

## SEC filing metadata
- accession: 0000950103-25-015818
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2025-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000095010325015818/0000950103-25-015818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000095010325015818/dp238449_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-015818
- JSON: https://secwatch.observer/filing/0000950103-25-015818.json
- Plain text: https://secwatch.observer/filing/0000950103-25-015818.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.